retatrutide phase 2 nejm 2023 percent weight loss 48 weeks 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No plateau — curve still descending Retatrutide for Obesity: Phase 2

(2017) 74(Pt A):7697

DSIP LIQUID SPRAY is manufactured under strict quality controls, ensuring purity and consistency, and contains a bioactive peptide formulation suitable for rigorous scientific studies

[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Mller M., Banning A., Brigelius-Floh R., Kipp A

doi: 10.3389/fimmu.2025.1528986

Public Interest in Using GLP-1 Drugs for Weight Loss Beyond the share who have used these drugs, much of the public has encountered GLP-1 drugs, with about four in ten (37%) adults saying they have a close friend or family member who is using one to either lose weight or treat a chronic condition